Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) Make an Investor Relations Push
Posted by Michael Sweeney on Thu, Mar 11, 2010 @ 05:10 PM
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA. At September 30, 2009, the Company had cash, cash equivalents, interest receivable and investment securities of $41.0 million, as compared to $22.7 million at December 31, 2008.
Over the last two to three weeks, the New York based company has been aggressive in getting the word out to the investment community about its prospects moving forward. Next week, CEO Ron Bentsur will be presenting at the 22nd Annual ROTH Ocean County Growth Stock Conference Laguna Niguel, CA. Keryx presented today at the Cowen and Company 30th Annual Health Care Conference in Boston, MA.
InvestorSoup.com recently announced an investment report featuring Keryx Biopharmaceuticals Inc.
Finally Rodman & Renshaw issied coverage on March1, 2010 with a "market outperform" rating.